ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tirbanibulin

Also written as “KX2-391”, “Tirbanibulin ointment 1%” and “KX01 ointment 1%”.

Its studies are mostly in Keratosis, Actinic · Warts · Psoriasis · Prostatic Neoplasms · Dermatitis, Phototoxic, led by 5 companies.

Drug pageTirbanibulin: every studyMany companies study it; this page follows only the 12 they lead. All 18 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 19, 202212 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Almirallits history only41 open or runningphase 4since May 19, 2022Mar 1, 2022Jul 2027phase 4 · NCT05387525
Athenexits history only30 open or runningphase 2since Feb 22, 2010Jan 15, 2008none ahead
PharmaEssentia30 open or runningphase 3since Jan 28, 2022Dec 30, 2021none ahead
Hanmi Pharmaceuticalits history only10 open or runningphase 2since Jan 2, 2013Jan 2, 2013none ahead
The Skin Center Dermatology Groupits history only10 open or runningphase 4since Jan 19, 2025Jan 19, 2025none ahead

Also a collaborator on its studies: PharmaEssentia Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of PharmaEssentia only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named tirbanibulinINNProposed as its International Nonproprietary Name in WHO's List 119 · before, KX2-391
  2. Dec 30, 2021First study: phase 1 study in Dermatitis, PhototoxicFirst studyNCT05245578 · 20 enrolled · Japan
  3. Jan 28, 2022Phase 3 study in Keratosis, ActinicNCT05231044 · 108 enrolled · Japan
  4. Aug 25, 2022Phase 1 study in PsoriasisNCT05522816 · 28 enrolled

TargetBeta

SRC →read by rule
“Tyrosine-protein kinase SRC inhibitor”ChEMBL 37, by rule

Other programs on SRC

ProgramCompanyFurthest phaseStudies
repotrectinibruleBristol-Myers Squibbphase 39
SRC/YES1 Kinase Inhibitor NXP900rulenuvectis-pharma-incphase 13

Studies

All 3 PharmaEssentia leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05522816Psoriasis1CompletedMar 10, 202128
NCT05231044Keratosis, Actinic · Japan3CompletedNov 20, 2023108
NCT05245578Dermatitis, Phototoxic · Japan1CompletedNov 22, 202120

How it is read

Names in the registry

  • “KX2-391”, 3 entries
  • “Tirbanibulin ointment 1%”, 2 entries
  • “KX01 ointment 1%”, 2 entries
  • “Tirbanibulin”, 1 entry
  • “KX01 0.01% (0.1 mg/g)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.